Fujiwara Shigeyoshi, Nakamura Hiroyuki
Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan.
Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, Tokyo 173-8610, Japan.
Pathogens. 2020 Feb 12;9(2):116. doi: 10.3390/pathogens9020116.
Epstein-Barr virus (EBV) is involved in the pathogenesis of various lymphomas and carcinomas, whereas Kaposi's sarcoma-associated herpesvirus (KSHV) participates in the pathogenesis of endothelial sarcoma and lymphomas. EBV and KSHV are responsible for 120,000 and 44,000 annual new cases of cancer, respectively. Despite this clinical importance, no chemotherapies or vaccines have been developed for virus-specific treatment and prevention of these viruses. Humans are the only natural host for both EBV and KSHV, and only a limited species of laboratory animals are susceptible to their experimental infection; this strict host tropism has hampered the development of their animal models and thereby impeded the study of therapeutic and prophylactic strategies. To overcome this difficulty, three main approaches have been used to develop animal models for human gammaherpesvirus infections. The first is experimental infection of laboratory animals with EBV or KSHV. New-world non-human primates (NHPs) and rabbits have been mainly used in this approach. The second is experimental infection of laboratory animals with their own inherent gammaherpesviruses. NHPs and mice have been mainly used here. The third, a recent trend, employs experimental infection of EBV or KSHV or both to immunodeficient mice reconstituted with human immune system components (humanized mice). This review will discuss how these three approaches have been used to reproduce human clinical conditions associated with gammaherpesviruses and to analyze the mechanisms of their pathogenesis.
爱泼斯坦-巴尔病毒(EBV)参与多种淋巴瘤和癌的发病机制,而卡波西肉瘤相关疱疹病毒(KSHV)则参与内皮肉瘤和淋巴瘤的发病机制。EBV和KSHV每年分别导致120,000例和44,000例新发癌症病例。尽管具有这种临床重要性,但尚未开发出针对这些病毒进行特异性治疗和预防的化疗药物或疫苗。人类是EBV和KSHV的唯一自然宿主,只有有限种类的实验动物易受它们的实验性感染;这种严格的宿主嗜性阻碍了它们动物模型的开发,从而妨碍了对治疗和预防策略的研究。为克服这一困难,已采用三种主要方法来开发人类γ疱疹病毒感染的动物模型。第一种是用EBV或KSHV对实验动物进行实验性感染。新大陆非人灵长类动物(NHPs)和兔子主要用于这种方法。第二种是用实验动物自身固有的γ疱疹病毒对其进行实验性感染。这里主要使用NHPs和小鼠。第三种,也是最近的一种趋势,是用EBV或KSHV或两者对用人免疫系统成分重建的免疫缺陷小鼠(人源化小鼠)进行实验性感染。本综述将讨论如何利用这三种方法来重现与γ疱疹病毒相关的人类临床状况,并分析其发病机制。